Harpoon Therapeutics logo
Harpoon Therapeutics HARP

Quarterly report 2023-Q3
added 11-09-2023

report update icon

Harpoon Therapeutics Cash Flow 2011-2026 | HARP

Annual Cash Flow Harpoon Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-89.2 M -122 M -8.62 M -2.89 M -27.1 M 1.71 M -10.8 M - - - - -

Depreciation & Amortization

2.36 M 2.19 M 2.08 M 900 K 644 K 366 K 198 K - - - - -

Accounts Payables

4.71 M 2.67 M 1.57 M 2.59 M 4.36 M - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Harpoon Therapeutics

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -19.3 M - -70.8 M -46.8 M -25.2 M - -105 M -84.6 M -18.1 M - 6.55 M 20 M -17.5 M - -36.6 M -25.4 M -12.4 M - -20.7 M -13.6 M -7.14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

200 K 400 K 662 K - 500 K 600 K 604 K - 1.63 M 1.1 M 549 K - 1.54 M 1.02 M 503 K - 400 K 596 K 297 K - 447 K 288 K 139 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

3.44 M 3.63 M 4 M 4.71 M 2.64 M 2.79 M 4.19 M 2.67 M 1.6 M 2 M 2.64 M 1.57 M 1.57 M 1.57 M 1.57 M 2.59 M 2.59 M 2.59 M 2.59 M 4.36 M 4.36 M 4.36 M 4.36 M 1.17 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Harpoon Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.89 - $ 6.54 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.2 - $ 3.68 B usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 15.9 - $ 50.8 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.76 - $ 27.9 M israelIsrael
Exelixis Exelixis
EXEL
$ 44.69 - $ 12.1 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 27.86 - $ 2.69 B belgiumBelgium
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.91 - $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 31.05 - $ 1.79 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 8.44 - $ 76.2 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 101.57 - $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.81 0.3 % $ 9.47 M australiaAustralia
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 99.1 - $ 19.3 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.7 - $ 1.71 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.33 - $ 32.9 M usaUSA
Innoviva Innoviva
INVA
$ 23.05 - $ 1.55 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.48 -0.67 % $ 235 M franceFrance
Jaguar Health Jaguar Health
JAGX
$ 7.88 - $ 18.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 26.67 - $ 1.44 B britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.11 - $ 260 M israelIsrael
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.98 - $ 4.91 M israelIsrael
Krystal Biotech Krystal Biotech
KRYS
$ 259.95 - $ 7.52 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 12.42 - $ 1.65 B australiaAustralia
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 224.86 - $ 4.11 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Liquidia Corporation Liquidia Corporation
LQDA
$ 38.15 - $ 3.28 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.05 - $ 433 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA